摘要
背景:帕金森病(PD)是一种神经退行性疾病,其特征在于黑质致密部(SNpc)内多巴胺能神经元的丧失。 尽管进行了许多研究,但仍无法治愈这种疾病。 左旋多巴是PD的第一线治疗,但长期使用它会导致运动障碍和运动障碍。 多巴胺激动剂是治疗PD的优选选择。 它们具有神经保护作用,但有副作用。 目的:我们的目的是回顾已经对多巴胺受体激动剂开展的工作以及减少其副作用的未来可能性。 结论:在这篇综述中,我们强调了多巴胺的代谢,不同类型的多巴胺激动剂及其特性和可能的副作用。
关键词: 神经退行性疾病,多巴胺,激动剂,代谢,神经递质,中枢神经系统。
Current Drug Targets
Title:Dopamine: Agonists and Neurodegenerative Disorders
Volume: 19 Issue: 14
关键词: 神经退行性疾病,多巴胺,激动剂,代谢,神经递质,中枢神经系统。
摘要: Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc). Despite many researches, there is still no cure for this disease. Levodopa is the first line treatment of PD, but the long term use of it leads to motor impairments and dyskinesias. The dopamine agonists are the preferred choice for the treatment of PD. They are neuroprotective in nature but have side effects.
Objective: Our aim was to review the work that has been carried out on dopamine agonists and the future possibilities to reduce their side effects.
Conclusion: In this review, we highlighted the metabolism of dopamine, different types of dopamine agonists with their properties and possible side effects.
Export Options
About this article
Cite this article as:
Dopamine: Agonists and Neurodegenerative Disorders, Current Drug Targets 2018; 19 (14) . https://dx.doi.org/10.2174/1389450118666171117124340
DOI https://dx.doi.org/10.2174/1389450118666171117124340 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential, Synthesis, Patent Evaluation and SAR Studies of Thieno[3,2-d]pyrimidine Derivatives: Recent Updates
Current Drug Targets Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Current Gene Therapy The Beneficial Effect of Rice Bran Extract Against Rotenone-Induced Experimental Parkinson’s Disease in Rats
Current Molecular Pharmacology Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology A Comprehensive Review on Preclinical Evidence-based Neuroprotective Potential of <i>Bacopa monnieri</i> against Parkinson's Disease
Current Drug Targets Molecular Docking Study of Catecholamines and [4-(Propan-2-yl) Phenyl]Carbamic acid with Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets Advances in the Physiology of GPR55 in the Central Nervous System
Current Neuropharmacology The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Clozapine and Olanzapine but not Risperidone Impair the Pre-Frontal Striatal System in relation to Egocentric Spatial Orientation in a Y-Maze
Current Neurovascular Research Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology Antipsychotics and Cognitive Functioning: A Critical Review
Current Psychopharmacology Pathological Gambling in Parkinson’s Disease: An Update on Medical Management
Current Psychopharmacology Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside
Current Neuropharmacology Pramipexole Tachyphylaxis and its Management in Bipolar Depression
Letters in Drug Design & Discovery